This work presents the production with a cyclotron of the positron emitter Co via the Fe(d,n) and Ni(p,α) reactions and the Auger electron emitter Co via the Fe(d,n) reaction after high current (40μA p and 60μA d) irradiation on electroplated targets. High specific activity radionuclides (up to 55.6 GBq/μmol Co and 31.8GBq/μmol Co) with high radionuclidic purity (99.995% Co from Fe, 98.8% Co from Ni, and 98.7% Co from Fe at end of bombardment, EoB), in high activity concentration (final separated radionuclide in < 0.6mL) and with almost quantitative overall activity separation yield (> 92%) were obtained after processing of the irradiated targets with novel radiochemical separation methods based on HCl dissolution and the resin N,N,N',N'-tetrakis-2-ethylhexyldiglycolamide (DGA, branched). One hour long irradiations using 38-65, 110-214 and 59-78mg of enriched Fe (99.93%), Ni (99.48%) and Fe (95.06%), respectively, electroplated over a 1.0cm surface, yielded 58 ± 66MBq Co, 372 ± 14MBq Co and 810 ± 186MBq Co, respectively, decay corrected to EoB. The separation methods allow for the recovery of the costly enriched target materials, which were reconstituted into metallic targets after novel electroplating methods, with an overall recycling efficiency of 93 ± 4% for iron. The produced radionuclides were used to radiolabel the angiogenesis marker antibody TRC105 conjugated to the chelator NOTA as a demonstration of their quality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673506 | PMC |
http://dx.doi.org/10.1016/j.apradiso.2017.09.005 | DOI Listing |
JCO Clin Cancer Inform
January 2025
SimBioSys Inc, Chicago, IL.
Purpose: Perfusion modeling presents significant opportunities for imaging biomarker development in breast cancer but has historically been held back by the need for data beyond the clinical standard of care (SoC) and uncertainty in the interpretability of results. We aimed to design a perfusion model applicable to breast cancer SoC dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) series with results stable to low temporal resolution imaging, comparable with published results using full-resolution DCE-MRI, and correlative with orthogonal imaging modalities indicative of biophysical markers.
Methods: Subsampled high-temporal-resolution DCE-MRI series were run through our perfusion model and resulting fits were compared for consistency.
J Chromatogr A
December 2024
Dalton Nuclear Institute, The University of Manchester, Oxford Road, Manchester M13 9PL, UK; Department of Mechanical, Aerospace & Civil Engineering, The University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Mass spectroscopy and microfluidic technology, when combined, offer significant advantages in radiochemical analysis sample volume and cost reduction. A microfluidic device designed for efficiency has been developed. This device separates uranium from key trace elements by utilising UTEVA® chromatographic resins and nitric acid solutions of different concentrations for adsorption and recovery.
View Article and Find Full Text PDFIndian J Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India.
Background: Prostate-specific membrane antigen (PSMA) has shown to be a promising agent for prostate cancer imaging under PET-CT. With the automation in radiolabeling with 68Ga, using iTG 68Ge/68Ga generator, it has helped introduce various new diagnostic agents and achieve good manufacturing practices (GMP) simultaneously. However, before any radiopharmaceutical is put into clinical usage, it should always be checked for its radiochemical purity and other quality parameters before injecting in the patient.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
The treatment regimen for [Lu]Lu-prostate-specific membrane antigen (PSMA) 617 therapy follows that of chemotherapy: 6 administrations of a fixed activity, each separated by 6 wk. Mathematic modeling can be used to test the hypothesis that the current treatment regimen for a radiopharmaceutical modality is suboptimal. A mathematic model was developed to describe tumor growth during [Lu]Lu-PSMA therapy.
View Article and Find Full Text PDFIn Vivo
December 2024
Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Background/aim: Angiogenesis imaging has been a valuable complement to metabolic imaging with 2-deoxy-2-[F]fluoroglucose (FDG). In our longitudinal study, we investigated the tumour heterogeneity and the relationship between FDG and [Ga]Ga-NODAGA-c(RGDfK) (RGD) accumulation in breast cancer xenografts.
Materials And Methods: Two groups of cell lines, a fast-growing (4T1) and a slow-growing cell line (MDA-MB-HER2+), were inoculated into SCID mice.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!